Journal ArticleDOI
Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin
Ruben Niesvizky,Andrew Spencer,Michael Wang,Donna M. Weber,C. Chen,M.A. Dimopoulos,Zhinuan Yu,Robert J. DeLap,J. Zeldis,Rob Knight +9 more
TLDR
The current study findings suggest that the administration of erythropoietic agents should be minimized in MM pts receiving Len/Dex, providing a longer median time to progression (TTP), higher response rates, and higher CR rates.Abstract:
7506 Background: Lenalidomide (Len) is a novel, orally administered, immunomodulatory drug (IMiD) that has single-agent activity against multiple myeloma (MM) and additive effects when combined wit...read more
Citations
More filters
Journal ArticleDOI
New Drugs for Myeloma
Paul G. Richardson,Constantine S. Mitsiades,Robert L. Schlossman,Nikhil C. Munshi,Kenneth C. Anderson +4 more
TL;DR: Clinical data available from studies of these drugs in the treatment of newly diagnosed and advanced multiple myeloma are focused on, with a view to assessing the safety and activity of combinations integrating these other novel agents.
Journal ArticleDOI
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Ma Dimopoulos,Antonio Palumbo,M. Attal,Meral Beksac,Fe. Davies,Michel Delforge,H. Einsele,Roman Hájek,J L Harousseau,F. Leal da Costa,Heinz Ludwig,U. H. Mellqvist,Gareth J. Morgan,Jesús F. San-Miguel,Sonja Zweegman,Pieter Sonneveld +15 more
TL;DR: Using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies, and long-term treatment until there is evidence of disease progression may be recommended at the best-tolerance doses of both lenalidomide and dexamethasone.
Journal ArticleDOI
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Heinz Ludwig,Meral Beksac,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Michele Cavo,Meletios A. Dimopoulos,Johannes Drach,Hermann Einsele,Thierry Facon,Hartmut Goldschmidt,Jean-Luc Harousseau,Urs Hess,Nicolas Ketterer,Martin Kropff,Larisa P. Mendeleeva,Gareth J. Morgan,Antonio Palumbo,Torben Plesner,Jesús F. San Miguel,Ofer Shpilberg,Pia Sondergeld,Pieter Sonneveld,Sonja Zweegman +23 more
TL;DR: This review presents an overview of the most recent data using the novel agents thalidomides, bortezomib, and lenalidomide in the treatment of multiple myeloma and summarizes European treatment practices incorporating these novel agents.
Journal ArticleDOI
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Sagar Lonial,Paul G. Richardson,Jesús F. San Miguel,Pieter Sonneveld,Michael W. Schuster,Joan Bladé,Jamie Cavenagh,Vincent Rajkumar,Andrzej Jakubowiak,Dixie-Lee Esseltine,Kenneth C. Anderson,Jean-Luc Harousseau +11 more
TL;DR: Preliminary data suggest bortezomib may reduce the thrombogenic potential of combination regimens via inhibition of platelet function or other mechanism‐specific effects on coagulation.
Journal ArticleDOI
The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma
TL;DR: This review focuses on results from key phase II and III trials of bortezomib, thalidomides, and lenalidomide alone or in combination, and their emerging role in improving outcomes.
Related Papers (5)
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Antonio Palumbo,Sara Bringhen,Tommaso Caravita,Emanuela Merla,Vincenzo Capparella,Vincenzo Callea,Clotilde Cangialosi,Mariella Grasso,Fausto Rossini,Monica Galli,Lucio Catalano,Elena Zamagni,Maria Teresa Petrucci,Valerio De Stefano,Manuela Ceccarelli,Maria Teresa Ambrosini,Ilaria Avonto,Patrizia Falco,Giovannino Ciccone,Anna Marina Liberati,Pellegrino Musto,Mario Boccadoro +21 more
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Paul G. Richardson,Robert L. Schlossman,Robert L. Schlossman,Edie Weller,Edie Weller,Teru Hideshima,Teru Hideshima,Constantine S. Mitsiades,Constantine S. Mitsiades,Faith E. Davies,Faith E. Davies,Richard Leblanc,Richard Leblanc,Laurence Catley,Laurence Catley,Deborah Doss,Deborah Doss,Kathleen Kelly,Kathleen Kelly,Mary McKenney,Mary McKenney,Julie Mechlowicz,Julie Mechlowicz,Andrea Freeman,Andrea Freeman,Reggie Deocampo,Reggie Deocampo,Rebecca Rich,Rebecca Rich,Joan J. Ryoo,Joan J. Ryoo,Dharminder Chauhan,Dharminder Chauhan,Kathe Balinski,Kathe Balinski,Jerome B. Zeldis,Jerome B. Zeldis,Kenneth C. Anderson,Kenneth C. Anderson +38 more